Pfizer's established brands, many of the medicines that drove the company's growth over the past two decades, are now part of its Upjohn division that is in the process of becoming a separate and standalone entity.
Upjohn's Gareth Richmond on creating the standalone entity
December 16, 2019 Latest NewsBioPharmaDispatch Executive
Latest Video
New Stories
-
A scrapped website, almost $100 million, and the politics of what really matters
November 23, 2025 - - Latest News -
Mesoblast to launch pivotal adult trial for cell therapy in severe steroid-refractory GVHD
November 22, 2025 - - Australian Biotech -
Syntara launches Phase 2 trial aiming to teduce transfusion burden in myelodysplastic syndromes
November 22, 2025 - -
Alterity Therapeutics chairman reflects on two decades of progress as company enters new era
November 22, 2025 - - BioPharma -
Treasurer blocks US takeover of Mayne Pharma on national interest grounds
November 22, 2025 - - Latest News -
If the system properly applied results in harm, then the problem is worse than we think
November 20, 2025 - - Latest News -
Silence in response to unethical processes and outcomes is itself unethical
November 20, 2025 - - Latest News
